medigraphic.com

2005, Number 1

<< Back Next >>

Arch Cardiol Mex 2005; 75 (1)

Study of myocardial viability: Comparison of PET and MRI

Meave A, Ricalde A, Sierra FC, García RCL, Alexánderson E

Language: Spanish
References: 28
Page: 71-78
PDF size: 68.13 Kb.


ABSTRACT

Background: In the last years, few methods for the assessment of myocardial viability have been developed. Now a days the gold standard test for this purpose is the Positron Emission Tomography (PET). Recently, the expansion of Cardiovascular Magnetic Resonance imaging (MRI) has promoted the research for indexes or scores than can predict myocardial viability; so far, the late enhancement has proved to be one of the most accurate scores. The purpose of this study is to establish a correlation between the information of PET with the results of MRI in the assessment of myocardial viability. Late enhancement patterns and segmental mobility were compared. Sensitivity, specificity and positive and negative predictive values were calculated. SPSS v. 10 program was used for the statistic analysis. Methods: 17 patients with diagnosis of myocardial infarction were enrolled. All of them underwent into a myocardial viability detection PET study and into a cardiovascular magnetic resonance study using a late enhancement technique. Results were interpreted by experts. The 17 segments model of The American Heart Association was used. Results: A total of 289 myocardial segments were analyzed, by PET 239 (82%) viable segments and 50 (17.3%) of non viable segments were detected, meanwhile by MRI 210 (72.6%) and 79 (27.4%) of viable and non viable myocardial segments respectively were found. Both techniques correlate 75% of the times and when vascular territories were analyzed, a good correlation was also established. Conclusions: MRI is an adequate technique to determine viability since it has good correlation with PET. This is the first study realized in Latin America that compares PET and MRI in the diagnosis of myocardial viability.


REFERENCES

  1. Rahimtoola SH: The hibernating myocardium. Am Heart J 1989; 117: 211–221.

  2. Lee K, Marwick T, Cook S, Go RT, Fix JS, James KB, et al: Prognosis of patients with left ventricular dysfunction with and without viable myocardium after myocardial infarction. Circulation 1994; 90: 2687-94.

  3. Stillman AE, ilke N, Jerosch-Herold M: Myocardial Viability. Radiol Clin North Am 1999; 37(2): 361-78.

  4. Beller GA: Noninvasive assessment of myocardial viability. N Engl J Med 2000; 343: 1487-1490.

  5. Alexanderson E, Gómez Martín D, Benito I, Ruiz Ramírez L, Ricalde A, Meave A: Tomografía por emisión de positrones (PET): Una herramienta útil para el estudio del metabolismo cardíaco. Arch Cardiol Mex 2004; 74: 220-228.

  6. Alexánderson E: Utilidad de las técnicas nucleares en el estudio de la viabilidad miocárdica. Arch Cardiol Mex 2004; 74(1): 8-12.

  7. Brunken R, Tillisch J, Schwaiger M, Child JS, Marshall R, Mandelkern M, et al: Regional perfusion, glucose metabolism and wall motion in patients with chronic electrocardiographic Q-wave infarction: evidence for persistence of viable tissue in some infarct regions by positron emission tomography. Circulation 1986; 73: 951-63.

  8. Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, et al: Reversibility of cardiac wall motion abnormalities predicted by positron tomography. N Engl J Med 1986; 314: 884-8.

  9. Carrel T, Jenni R, Haubold-Reuter S, Von Schultess G, Pasic M, Turina M: Improvement of severely reduced left ventricular function after surgical revascularization in patients with preoperative myocardial infarction. Eur J Cardiothorac Surg 1992; 6: 479-84.

  10. Lucignani G, Paolini G, Landoni C, Zuccari M, Paganelli G, Galli L, et al: Presurgical identification of hibernating myocardium by combined use of technetium-99m hexakis 2-methoxyisobutyl isonitrile single photon emission tomography and fluorine-18 fluoro-2-deoxyglucose positron emission tomography in patients with coronary artery disease. Eur J Nucl Med 1992; 19: 874-81.

  11. Camici P, Ferrannini E, Opie LH: Myocardial metabolism in ischemic heart disease: basic principles and application to imaging by positron emission tomography. Prog Cardiovasc Dis 1989; 32: 217-38.

  12. Fitzgerald J, Parker A, Danias P: F-18 fluoro deoxyglucose SPECT for assesment of myocardial viability. J Nucl Cardiol 2000; 7(4): 382-7.

  13. Tamaki N, Kawamoto M, Tadamura E, Magata Y, Yonekura Y, Nohara R, et al: Prediction of reversible ischemia after revascularization: perfusion and metabolic studies with positron emission tomography. Circulation 1995; 91: 1697-705.

  14. Tamaki N, Yonekura Y, Yamashita K, Saji H, Magata Y, Senda M, et al: Positron emission tomography using fluorine-18 deoxyglucose in evaluation of coronary artery bypass grafting. Am J Cardiol 1989; 64: 860-865.

  15. Gropler RJ, Geltman EM, Sampathkumaran K, Perez JE, Schechtman KB, Conversano A, et al: Comparison of carbon-11-acetate with fluorine-18-fluorodeoxyglucose for delineating viable myocardium by positron emission tomography. J Am Coll Cardiol 1993; 22: 1587-1597.

  16. Marwick TH, MacIntyre WJ, Lafont A, Nemec JJ, Salcedo EE: Metabolic responses of hibernating and infarcted myocardium to revascularization: a follow-up study of regional perfusion, function, and metabolism. Circulation 1992; 85: 1347-1353.

  17. Akinboboye OO, Idris O, Cannon PJ, Bergmann SR: Usefulness of Positron Emission Tomography in Defining Myocardial Viability in Patients Referred for Cardiac Transplantation. Aml Cardiol 1999; 83: 1271-1274.

  18. Di Carli MF, Asgarzadie F, Schelbert HR, Bruken RC, Laks H, Phelps MF, et al: Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation 1995; 92: 3436-3444.

  19. López Lereu M, Boda V, Sanchos J, García D, Pellicer M, Losada A, et al: Fiabilidad de los índices de viabilidad miocárdica por resonancia magnética para predecir la mejoría de la función sistólica en pacientes con un primer infarto reciente y arteria abierta. Rev Esp Cardiol 2004; 57: 826-33.

  20. Kim R, Wu E, Rafael A, Chen E-L, Parker M, Simonetti O, et al: The use of contrast - enhanced magnetic resonante imaging to identify reversible myocardial dysfunction. N Engl J Med 2000; 343: 1445-53.

  21. Selvanayagam J, Kardos A, Francis J, Wiesmann F, Petersen S, Taggart D, et al: Value of delayed – enhanced cardiovascular magnetic resonance imaging in predicting myocardial viability after surgical revascularization. Circulation 2004; 110: 1535-1541.

  22. Wagner A, Mahrholdt H, Holly TA, Elliot M, Regenfus M, Parker M, et al: Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet 2003; 361: 374-79.

  23. Dilsizian V, Rocco TP, Freedman NM, Leon MB, Bonow RO: Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging. N Engl J Med 1990; 323: 141-146.

  24. Ragosta M, Beller GA, Watson DD, Kaul S, Gimple LW: Quantitative planar rest – redistribution 201TL imaging in detection of myocardial viability and prediction of improvement in left ventricular function after coronary bypass surgery in patients with severely depressed left ventricular function. Circulation 1993; 87: 1630-41

  25. Kuhl HP, Beek AM, Van der Weerdt AP, Hofman MB, Visser CA, Lammertsma AA, et al: Myocardial viability in chronic ischemic heart disease: a comparison of contrast enhanced magnetic resonance imaging with (18) FDG PET. JACC 2003; 16: 1341-1348.

  26. Cerqueira M, Weissman N, Dilsizian V, Jacobs A, Kaul S, Laskey W et al: Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002; 105: 539-42.

  27. 27.Schelbert HR, Beanlands R, Bengel F, Knuuti J, Di Carli M, Machac J, et al: Pet myocardial perfusion and glucose metabolism imaging: part 2-guidelines for interpretation and reporting. J Nucl Cardiol 2003; 10(5): 557-71.

  28. Brix G, Zaers J, Adam LE, Bellemann ME, Ostertag H, Trojan H, et al: Performance evaluation of the whole-body PET scanner. J Nucl Med 1997; 38(10): 1614-23.




2020     |     www.medigraphic.com